Cytokinetics
CYTK
380 hedge funds and large institutions have $7.75B invested in Cytokinetics in 2025 Q3 according to their latest regulatory filings, with 101 funds opening new positions, 126 increasing their positions, 102 reducing their positions, and 26 closing their positions.
312% more call options, than puts
Call options by funds: $361M | Put options by funds: $87.6M
288% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 26
70% more capital invested
Capital invested by funds: $4.55B → $7.75B (+$3.2B)
33% more funds holding in top 10
Funds holding in top 10: 12 → 16 (+4)
24% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 102
22% more funds holding
Funds holding: 311 → 380 (+69)
2.5% more ownership
Funds ownership: 115.28% → 117.77% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$75.1M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$60.9M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$59.1M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$26.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$92.7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$52.2M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$47.4M |
| 4 |
O
OrbiMed
New York
|
-$35.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$31.1M |
CYTK Hedge Fund Activity: Q3 2025 in Review
380 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2025, worth a combined $7.75B — up 70% from $4.55B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new CYTK positions and 26 closed out — a net gain of 75 holders — while 126 added to existing stakes and 102 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $75.1M. The largest seller was Vestal Point Capital, cutting an estimated $92.7M.
- 380 institutional investors held Cytokinetics (CYTK) as of Q3 2025, up from 311 in Q2 2025.
- Funds reported $7.75B of Cytokinetics stock for Q3 2025, up 70% quarter-over-quarter.
- 101 funds opened new Cytokinetics positions in Q3 2025 and 26 closed out, a net change of +75 holders.
- The largest Cytokinetics buyer in Q3 2025 was Fidelity Investments, an estimated $75.1M added.
- The largest Cytokinetics seller in Q3 2025 was Vestal Point Capital, an estimated $92.7M sold.
Based on aggregated 13F filings for Q3 2025.